BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12170192)

  • 1. Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
    Gruss C; Geissler A; Schalke B; Landthaler M; Stolz W
    Melanoma Res; 2002 Aug; 12(4):403-4. PubMed ID: 12170192
    [No Abstract]   [Full Text] [Related]  

  • 2. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
    Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M
    Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment and other combination regimens.
    Bajetta E; Del Vecchio M; Bajetta R; Canova S
    Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
    Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study.
    Bröcker EB; Bohndorf W; Kämpgen E; Trcka J; Messer P; Tilgen W; Engenhart K; Flentje M
    Melanoma Res; 1996 Oct; 6(5):399-401. PubMed ID: 8908601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
    Ulrich J; Gademann G; Gollnick H
    J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
    Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
    Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
    [No Abstract]   [Full Text] [Related]  

  • 10. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
    Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
    Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
    Bonenkamp JJ; Thompson JF; de Wilt JH; Doubrovsky A; de Faria Lima R; Kam PC
    Eur J Surg Oncol; 2004 Dec; 30(10):1107-12. PubMed ID: 15522559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
    Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Bui BN; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre ME; De Gislain C; Bensadoun RJ; Clavel M
    Melanoma Res; 2003 Feb; 13(1):97-103. PubMed ID: 12569292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study.
    Khayat D; Cour V; Bizzari JP; Aigner K; Borel C; Cohen-Alloro G; Weil M; Auclerc G; Buthiau D; Bousquet JC
    Am J Clin Oncol; 1991 Oct; 14(5):400-4. PubMed ID: 1951178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association of radiation- and fotemustine-therapy in the management of brain metastases from non-small-cell cancers of the lung].
    Pignon T; Astoul P; Ruggieri S; Vialette JP; Orabona P; Muracciole X; Boutin C; Juin P
    Bull Cancer Radiother; 1994; 81(1):49-51. PubMed ID: 7893524
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 17. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.
    Addeo R; Zappavigna S; Luce A; Facchini S; Caraglia M
    Expert Opin Drug Saf; 2013 Sep; 12(5):729-40. PubMed ID: 23560594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.